Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLM3003 in mild or moderate atopic dermatitis
NCT06058000Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QLM3003 in atopic dermatitis (AD) (5 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score at 8 weeks. Started Nov 2023; status: completed.
02
Drugs
QLM3003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06058000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058000.